KLRA Kailera Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$23.18

Period return

-2.82 (-10.85%)

Volume

297.2K

2026-06-01O $22.89 H $23.66 L $22.28 C $23.18MA5 $22.51MA20 $22.05

6M · 31 barsYahoo Finance · USD2026-04-17 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 13.MediumBUY20 days ago
Leerink Partners: Outperform
US analyst rating / recommendation change.
2026. 05. 13.MediumBUY20 days ago
Jefferies: Buy
US analyst rating / recommendation change.
2026. 05. 13.MediumBUY20 days ago
Evercore ISI Group: Outperform
US analyst rating / recommendation change.
2026. 05. 12.MediumBUY20 days ago
JP Morgan: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $42.6 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
HQ: Waltham, MA, United States
Fiscal year end: —
Employees: 145
IPO date: —

View details →

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 13.	Leerink Partners	—	Initiate coverage	— → Outperform	—	Leerink Partners: Outperform
2026. 05. 13.	Jefferies	—	Initiate coverage	— → Buy	—	Jefferies: Buy

Kailera Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

See full research history

Key stats

See the key changes, summarized by AI

See all institutional holding changes